資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34397
|
| 標題: | Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia |
| 作者: | Chen, Pei-Yi
Gao, Wan-Yun
Liou, Je-Wen
Lin, Ching-Yen
Wu, Ming-Jiuan
Yen, Jui-Hung |
| 貢獻者: | Buddhist Tzu Chi Med Fdn, Hualien Tzu Chi Hosp, Ctr Med Genet
Tzu Chi Univ, Dept Mol Biol & Human Genet
Tzu Chi Univ, Inst Med Sci
Tzu Chi Univ, Sch Med, Dept Biochem
Chia Nan Univ Pharm & Sci, Dept Biotechnol |
| 關鍵字: | dyslipidemia
TG-rich lipoproteins
ASCVDs
ANGPTL3
lipoprotein lipase |
| 日期: | 2021 |
| 上傳時間: | 2023-11-11 11:49:34 (UTC+8) |
| 出版者: | MDPI |
| 摘要: | Dyslipidemia is characterized by increasing plasma levels of low-density lipoprotein-cholesterol (LDL-C), triglycerides (TGs) and TG-rich lipoproteins (TGRLs) and is a major risk factor for the development of atherosclerotic cardiovascular disorders (ASCVDs). It is important to understand the metabolic mechanisms underlying dyslipidemia to develop effective strategies against ASCVDs. Angiopoietin-like 3 (ANGPTL3), a member of the angiopoietin-like protein family exclusively synthesized in the liver, has been demonstrated to be a critical regulator of lipoprotein metabolism to inhibit lipoprotein lipase (LPL) activity. Genetic, biochemical, and clinical studies in animals and humans have shown that loss of function, inactivation, or downregulated expression of ANGPTL3 is associated with an obvious reduction in plasma levels of TGs, LDL-C, and high-density lipoprotein-cholesterol (HDL-C), atherosclerotic lesions, and the risk of cardiovascular events. Therefore, ANGPTL3 is considered an alternative target for lipid-lowering therapy. Emerging studies have focused on ANGPTL3 inhibition via antisense oligonucleotides (ASOs) and monoclonal antibody-based therapies, which have been carried out in mouse or monkey models and in human clinical studies for the management of dyslipidemia and ASCVDs. This review will summarize the current literature on the important role of ANGPTL3 in controlling lipoprotein metabolism and dyslipidemia, with an emphasis on anti-ANGPTL3 therapies as a potential strategy for the treatment of dyslipidemia and ASCVDs. |
| 關聯: | INT J MOL SCI, v.22, n.14 |
| 顯示於類別: | [生物科技系(所)] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| ijms-22-07310.pdf | | 1590Kb | Adobe PDF | 48 | 檢視/開啟 | | index.html | | 0Kb | HTML | 106 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
